Not sure if Sarepta sees Audentes as a threat in DMD given they’re preclinical and Sarepta already has plenty in the pipeline ?
Sarepta seem to have heavily pivoted the last few years building their gene therapy strong hold though so maybe just didn’t fit with them anymore ? Audentes buy out last night was big for Sarepta or all gene therapy companies really as the buy out spree continues.
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-36
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 12.0¢ | $185.3K | 1.515M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 166662 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 39575 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |